Background-Hepatoblastoma is a rare, rapidly progressive, usually fatal childhood malignancy, which if confined to the liver can be cured by radical surgical resection. An association between hepatoblastoma and familial adenomatous polyposis (FAP), which is due to germline mutation of the APC (adenomatous polyposis coli) gene, has been confirmed, but correlation with site of APC mutation has not been studied. Conclusions-Hepatoblastoma occurs primarily in boys in FAP kindreds and is associated with germline APC mutation in the 5' end of the gene. However, the site of APC mutation cannot be used to predict occurrence of this extracolonic cancer in FAP pedigrees.
Familial adenomatous polyposis (FAP) is an autosomal dominant disorder characterised by the development during adolescence and young adulthood of hundreds to thousands of colorectal adenomas.' If prophylactic colectomy is not performed, virtually all affected subjects will develop colorectal cancer by the fifth decade of life. FAP can be associated with extraintestinal lesions ('Gardner syndrome') such as soft tissue and bony tumours; desmoid tumours; and extracolonic cancers of the thyroid, duodenum, pancreas, liver, and brain. [1] [2] [3] [4] Hepatoblastoma is a rare malignant embryonal tumour of the liver, which occurs in infancy and childhood. An association between hepatoblastoma and familial adenomatous polyposis was first described by Kingston et Methods Data were collected from The Johns Hopkins Polyposis Registry, which contains 382 pedigrees with familial adenomatous polyposis. Patient information was obtained on all registry subjects through chart review and was subsequently computerised. The diagnosis of hepatoblastoma in the study population was verified by review of the original pathology slides (n=7) or report if the original slides were not available (n=l). Seven of the cases were reported in our previous publication.7
Genotyping was done from peripheral blood leucocytes in one affected member with FAP from each family after informed consent was obtained. In five families, genomic DNA was evaluated for germline mutations by RNase protection assay after polymerase chain reaction amplification and then sequenced.40 41 In two families, the APC mutation was identified by in vitro synthesis protein assay,42 as described previously, and the site of mutation was estimated from the size of the truncated product.
The frequency of pedigrees with (n=7) and without hepatoblastoma (n=97) in the Registry was compared with the site of mutations in the APC gene by x2 analysis. Correlation of age and survival with site of APC mutation was examined by calculation of Spearman's rank correlation coefficients.
Results
The Table lists the patients with hepatoblastoma in our Registry.7 All patients had one parent with FAP and therefore were at 50% risk for the development of this autosomal dominant disorder. Six of eight patients were male and all were white, but there were no statistically significant differences in demographics between these patients and the Registry population. When all literature cases (24 males, nine females with hepatoblastoma) were compared with the Registry population, there was a statistically significant predominance of male patients (p<0 01). All patients in the current series were diagnosed with hepatoblastoma before 10 years of age. Three patients survived hepatic resection and manifested adenomatous polyposis of the large bowel at 8X8, 13-6, and 18.0 years of age. The other five patients died within the first seven years of life and had no clinical evidence of colorectal polyposis. The expected because of their young ages; the average age of diagnosis of adenomas in at risk subjects is 15 years of age.'
Mutation of the APC gene was found in all seven kindreds with a member who had hepatoblastoma. The mutations were restricted to codons 141 to 1230, and all resulted in a truncated APC protein. Although no family with hepatoblastoma had a mutation 3' to codon 1230, there was no statistically significant increase in frequency of hepatoblastoma in registry pedigrees with mutations in codons 1 to 1230 (seven of 83) compared with families with mutations in codons 1231 to 2843 (0 of 21) (p=0. 34) . No significant correlations between site of mutation and age at diagnosis of hepatoblastoma or length of survival after diagnosis were found.
Discussion
Hepatoblastoma is a rapidly progressive tumour that carries a grave prognosis when malignancy has spread beyond surgical resection.6 In contrast, if diagnosed early, this tumour is potentially curable with surgery, as occurred in two of our eight FAP patients who had longterm survival. Intensive screening of infants and children in FAP pedigrees with high risk for hepatoblastoma could be accomplished if it were possible to identify subjects on the basis of their APC mutation.
In our study, hepatoblastoma occurred primarily in male patients (six of eight), which is similar to the male predominance noted in literature cases (18 of 25) . This predominance suggests that diagnostic attention to hepatomegaly on physical examination or abnormalities of liver chemistries deserve particular attention in boys in FAP families. Furthermore, APC mutations in our pedigrees with hepatoblastoma were restricted to codons 141 to 1230. Characterisation of the spectrum of APC mutations in additional FAP families with hepatoblastoma is needed to determine if this restriction can serve as a basis for surveillance because, the distribution of mutations was not statistically different from the site of mutations in pedigrees without hepatoblastoma. 
